Millions of people suffer from sleep apnea every single night
We will not rest until they sleep peacefully
Temp Menu
Restera is a clinical-stage medical technology company developing a first-of-its-kind treatment for sleep apnea.
Restera has united a world-class team of clinicians, engineers, investors, and leading research institutions with a shared mission: to deliver a transformative treatment for Obstructive Sleep Apnea (OSA).
Restera’s Board of Directors brings deep operational, clinical, and financial expertise across the medical technology and life sciences sectors. The company’s Scientific Advisory Board includes leading experts from renowned institutions such as the University of Pennsylvania, Vanderbilt University, Stanford University, Flinders University, and Monash University.
Sleep Apnea is a Significant Global Problem
One Billion
Sleep apnea sufferers worldwide
Current solutions are not working. Continuous positive airway pressure (CPAP) therapy accounts for 85% of diagnosed sleep apnea patients, yet nearly half don’t comply with the therapy. The devices are cumbersome, loud, uncomfortable and overall intrusive.
Eighty Percent
Remain undiagnosed
When untreated, sleep apnea is linked to serious and costly conditions, including drug-resistant hypertension, obesity, congestive heart failure, type-2 diabetes, atrial fibrillation and more.
$150 Billion
Economic impact of sleep apnea in the US
Untreated sleep apnea costs the U.S. approximately $150 billion annually, due to the healthcare costs associated with these untreated conditions, as well as loss of productivity, workplace accidents and motor vehicle accidents.
A miniature device, placed perfectly in minutes, allows the airways to open significantly, enabling greatly improved breathing.
Our therapy leverages safe, well-established neurostimulation technology in a miniature implant designed for a quick, 15-minute outpatient procedure. The device is injected in a simple procedure, leaving no visible scars and enabling patients to return to daily life with minimal disruption.
During sleep the tiny implant provides stimulation at just the right levels to cause the muscles to move and open the airway.
Restera is Working on a Transformative Solution
Clinical Studies
How is it different?
Over 5 years of rigorous clinical work led to significant progress in two key areas:
The patented position of our miniature device in relation to the patient’s neural anatomy provides measurably better results
Our patented, innovative tools and methods to allow for a quick, accurate placement of the device in minutes in an outpatient setting
In addition, we are pioneers in working with the Ansa Cervicalis (AC) nerve which provides significant additional therapeutic options when considered together with the Hypoglossal nerve (HGN).
What sleep experts are saying:
“We consistently demonstrated quite remarkable improvements in airflow where acute stimulation was able to consistently completely reopen the airway and restore airflow from complete collapse (apnea).
”
Learn more about our team and clinical work:
Executive Team and Board
